Compare Rigetti Computing Inc (RGTI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Summit Therapeutics Inc — how do they compare? Rigetti Computing Inc trades at $14.03 (market cap $4.72B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.9× Rigetti Computing Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rigetti Computing Inc for 35 Days and Summit Therapeutics Inc for 16 Days on average.
| RGTI | SMMT | |
|---|---|---|
Market Cap | $4.72B | $13.71B |
Volume | 17,136,381 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $56.34 | $26.38 |
52-Week Low | $12.90 | $12.43 |
Typical Hold Time | 35 Days | 16 Days |
Enterprise Value | $4.33B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGTI trades at $14.03, down 3.84% with bearish technical signals despite bullish oscillators. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income) and negative margins. Analyst consensus remains strong with 85.71% buy ratings and $21.67 price target, while recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC partnerships.
RGTI presents high-risk speculative potential with Wall Street optimism contrasting weak fundamentals. The stock offers substantial upside to analyst targets but faces execution risks in commercializing quantum technology amid persistent cash burn and competitive pressures from better-funded peers.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
